Gene edit­ing for heart dis­ease: Verve kicks off land­mark base edit­ing tri­al

Verve Ther­a­peu­tics has dosed the first pa­tient with its lead car­dio­vas­cu­lar drug, mark­ing a ma­jor mile­stone for the next-gen gene edit­ing tech­nique known as base edit­ing.

Now of­fi­cial­ly in a Phase Ib clin­i­cal tri­al in New Zealand, VERVE-101 is a sin­gle base ed­i­tor de­signed to per­ma­nent­ly turn off the PC­SK9 gene in pa­tients with het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia, who have dan­ger­ous­ly high cho­les­terol lev­els.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER